May 25th 2023
According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Cases and Conversations™: New Treatment Strategies for nAMD & DME
07/28/2023
View More
Ophthalmology Consultations™: Keeping an Eye Out for MGD-Associated Dry Eye in Pre/Post-Op Patients – Improving Surgical Outcomes by Optimizing the Surface
View More
Community Practice Connections™: Inflammation & Pathogenesis in DME – Rethinking the Traditional Treatment Paradigm
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
Comprehensive Key Advances in Biosimilars for Retinal Diseases – Reviewing the Evidence, Addressing Patient Perspectives, and Practice Utilization for the Retina Specialist
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(COPE Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
Cases & Conversations™: Inflammation & Pathogenesis in DME – Rethinking the Traditional Treatment Paradigm
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME Credit) Community Practice Connections™: Understanding Emerging Options in MGD-Associated Dry Eye Disease—Preparing for an Updated Armamentarium
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(CME/CNE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
(COPE Credit) Expert Illustrations & Commentaries™: Visualizing the Angiopoetin-Tie2 Pathway as a Target in Retinal and Choroidal Vascular Diseases
View More
FDA approves intravenous injection for delayed onset of stage 3 type 1 diabetes
November 18th 2022Teplizumab may work by binding to certain immune system cells that attack insulin-producing cells and increase the proportion of cells that help moderate the immune response, thus delaying progression to stage 3 type 1 diabetes.
Patient education vs patient relations?
September 9th 2020• Relatable patient education improves quality of care and prognosis • Although patients with moderate NPDR without DME can be followed every 6 to 9 months, when macular involvement is present patient needs more frequent follow-up • Patients with diabetic retinopathy need to be informed about importance of follow-up care even in the absence of their vision changes